chrisvoncsefalvay/vaers-outcomes huggingface dataset:
"Several hours after receiving vaccine had fever 100.1", she states, "vomiting during noc, achy, chills for 3 days."
"Moderna COVID-19 Vaccine EUA"  The event is listed as "administration error/deviation" and no known adverse advents have been noted at this time. On 7-23-21 the listed patient presented to Urgent Care for the second dose of his Moderna immunization sequence. The vaccine was pulled from a vial that was initially opened at approximately 2pm on 7-21-2021. The medical assistant on staff that day had failed to discard the vial after the 12 hour window from initial puncture. The same vial was consistently refrigerated from it's initial puncture but was used outside of the 12 hour window as it was punctured again on 7-24-21 around approximately 4pm for the patients second dose. The MA on duty did not realize the vial was outside of the time window from initial puncture. The patient was held for 15 minutes in the office with no adverse effects. He was stable upon discharge and reported no symptoms upon leaving the clinic. Since that time the patient has been contacted multiple times by phone and email but our staff has been unable to reach him due to his phone disconnection. Moderna was notified of the event and the medical team advised the second Vaccine is still valid requiring no repeat dosing. The only adverse effect they advised to monitor for was infection as the vial was kept refrigerated the entire time but still lacks preservative.
Got COVID after having the first two doses; Hit him pretty hard; Pretty sick; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Got COVID after having the first two doses), VACCINATION COMPLICATION (Hit him pretty hard) and ILLNESS (Pretty sick) in a male patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Got COVID after having the first two doses), VACCINATION COMPLICATION (Hit him pretty hard) and ILLNESS (Pretty sick). At the time of the report, COVID-19 (Got COVID after having the first two doses), VACCINATION COMPLICATION (Hit him pretty hard) and ILLNESS (Pretty sick) outcome was unknown.        mRNA-1273 (Spikevax) (Unknown) was withdrawn on an unknown date.       Concomitant and treatment medication of the patient was not reported.  The patient reported that about 5 months ago (from the date of reporting), his car got broken into and his wallet was stolen with vaccination card. The patient also reported that, he was not going to get the booster.  Company comments:This case concerns a male patient of unknown age, with no reported medical history, who experienced the unexpected, non-serious, AESI event of COVID-19, on an unknown date after receiving two doses of mRNA-1273.  The dates of both doses were unknown.   Clinical course and treatment were not reported in this case.  Additionally, patient reported unspecified non-serious side effects after both doses. At the time of the report, the outcome of the event of COVID-19 was unknown.  The benefit-risk relationship of mRNA-1273 is not affected by this report   This case was linked to MOD-2022-522464 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 24-Mar-2022: Follow-up information contains addition of reporter's phone number.; Sender's Comments: This case concerns a male patient of unknown age, with no reported medical history, who experienced the unexpected, non-serious, AESI event of COVID-19, on an unknown date after receiving two doses of mRNA-1273.  The dates of both doses were unknown.   Clinical course and treatment were not reported in this case.  Additionally, patient reported unspecified non-serious side effects after both doses. At the time of the report, the outcome of the event of COVID-19 was unknown.  The benefit-risk relationship of mRNA-1273 is not affected by this report
Several weeks after my 2nd Pfizer Covid-19 vaccination I developed fingernail irregularities on my right hand, later diagnosed as Beau's lines.  I do not remember the specific date this appeared.  It started with purple/red color on four fingernails in the half moon area.  Later turned white and one nail came off, with another growing underneath. At some point the Beau's lines appeared.  By the time I got an appointment with my dermatologist, at the suggestion of my primary care doctor,  for diagnosis, significant time had gone by.  Around the same time after the vaccine,  I developed very painful headaches we are attributing to tight neck muscles, but I have never been a headache person before and these headaches are very debilitating  and unlike  any headache I have ever experienced, even though I have not been a frequent headache sufferer . I understand that Beau's lines have been associated with Covid iteslf,  but I highly doubt I had Covid itself.  I have had, in the past, very very rare side effects to medications and I have broken out in hives from the pneumonia vaccine  I had had before, several years ago.
Patient contacted clinic the day following immunization to report that her arm was "really, really sore" indicating that she had never experienced this kind of pain before. Symptomatic therapy with warm packs alternating with ice as well as acetaminophen to use as needed discussed. Patient later noted that one hour after the shot she started to feel tingling in her left arm (site of injection). Within a few hours there was notable pain radiating from elbow to shoulder. There was no swelling, red streaks, or warmth. Described pain October 9 as a "band with one intense point." No changes in mobility, but noted discomfort carrying items weighing less than 5 pounds and with lifting arm overhead as well as repositioning in bed. Seen in clinic 10/12/2023 with pain to left shoulder superior medial area or deltoid. Decreased ROM to 90 degrees. No other abnormalities noted on exam. Prescribed Naproxen 220 mg bid and alternate with acetaminophen as well as initiating physical therapy. After 4th session of physical therapy feels pain may now be improving slightly.
generally felt bad and tired, some soreness at injection site, red spot on the left arm with a small lump (not at injection site) the red spot is still visible, had fever the day after shot.  Day of  the shot I slept all day and that night.
The following day after receiving the Pfizer Booster shot in my left arm, the glands on the left side of my neck were very swollen and sore.  My left earlobe was also swollen and tender.  The swelling in my neck and earlobe continued until January 19, 2022.  Today, January 20, 2022, the swelling in my neck has subsided but I have developed a sore under my left earlobe.  I have also begun to develop what feels like an ear infection in my left ear.
dermatologic reaction, multiple itchy erythematous patches on left leg (calf up to knee)
Vaccination site pruritus; Vaccination site rash; This spontaneous case was reported by a consumer and describes the occurrence of   in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no relevant medical history provided).    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
being nauseous and having a few bowels movements each day; being nauseous and having a few bowels movements each day; This is a spontaneous report from a contactable consumer (patient). A 74-year-old female received second dose of bnt162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/lot number: EL9262 expiry date: unknown) via an unspecified route of administration into the right arm, on 24Jan2021, as a single dose for covid-19 immunization. Medical history included Mitral valve replacement and GERD from unknown date and unknown if ongoing. Concomitant medications included WARFARIN SODIUM (COUMADIN) 9mg four days a week, 5mg three days a week, by mouth for Mitral valve replacement; and DEXLANSOPRAZOLE (DEXILANT) 60mg, once daily by mouth for GERD since Oct2020. Historical vaccine included patient's first dose of BNT162B2 (Solution for injection, Batch/lot number: EH9899 expiry date: unknown) via an unspecified route of administration, on 03Jan2021, as a single dose for covid-19 immunization. On Sunday 24Jan2021, she got her second dose of the COVID vaccine, and starting on 25Jan2021 Monday, going on through the day of this report, the patient had been nauseous, and she was having quite a few bowel movements, although did not have diarrhea. The patient did not undergo any investigation. she received no other vaccines on the same day as the COVID vaccine. The outcome of the events was not recovered.  Follow-up (16Apr2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
APPROX 5-10 MINS LATER AFTER ADMINISTRATION, EXPERIENCED LIGHTHEADNESS, DIZZINESS, FEELING OF MALIASE, GROGGINESS, THEN  15 MINS LATER THEN DRUNKINESS FEELING WHICH PERSISTED FOR 45 MINS.  BACK TO BASELINE 1HR 15 MINS AFTER INJECTION
Within 15 minutes of shot she felt very ill. L arm swelling, numbness of injected arm, throat swelling, tongue swelling, headache, eyes watering, itchy. Sent to ER. She was given medication to treat her symptoms but she doesn't remember the type of medication. One month later she developed muscle and joint aches, headaches of migraine type. Her tongue and throat continue to swell. She developed dark black vaginal bleeding and was told she had ovarian cysts. She has been diagnosed with fibromyalgia. She reports that a VAERS has been filed. She has been evaluated and determined to be non-deployable and medically retired from the military. She was given Lupron for her ovarian cysts and vaginal bleeding. Both of these symptoms have resolved. Follow-up received 5/9/06. Subject reports "I am disable now". 60 day Follow-up Information 24-OCT-2006: No further information on this report. In the event that additional relevant medical information is received, a follow-up report will be submitted.
I had fever, chills, back ache, muscle aches, and nerve pain every since my second vaccine.
Information has been received through the Merck pregnancy registry concerning a 30 year old black female with hypertension, a history of 2 pregnancies and 1 live birth (1 miscarriage at 10.5 weeks), and no known allergies, who on 10-JUN-2002 was vaccinated with a dose of varicella virus vaccine live. There was no local reaction at the vaccination site, and no symptoms of varicella or herpes zoster post vaccination. The patient was not tested for varicella antibodies before being vaccinatied with varicella virus vaccine live. Concomitant medication for hypertension included amlodipine besylate (NORVASC) 2.5 mgs dialy, (also reported as taking for 3 years) and metoprolol succinate (TOPROL XL TABLETS) 50mg BID. On 15-JUN-2002 the patient took an early home pregnancy test, and it came out positive. She reported that she was going to contact her physician to find out if she was really pregnant. She noted that her LMP was 17-MAY-2002. No medical attention was sought. Information was received on 02-JUL-2002 from her physician that noted her LMP was 13-MAY-2002. It was reported that there was no birth defects in any previous pregnancy. A screening ultrasound was scheduled for the first week in July 2002 and was reported as normal. On 12-Sep-2003, a screening maternal serum alpha fetal protein test was reported as normal. On 15-FEB-2003, at 39 weeks, the patient delivered a normal, 5lb., 14 oz. female. The infant had no congenital anomalies, complications or abnormalities, nor any features of congenital varicella zoster syndrome. The patient developed hyperemesis and hypotension during her pregnancy. There were no other reported complications, infections or illnesses during her pregnancy. No further information is expected.
Patient alleges she developed mild urticaria initially over entire torso then gradually to all extremities. Several days later patient alleges she developed severe fatigue and muscle weakness.
This spontaneous report as received from a Registered Nurse refers to a 18 months old female patient. The patient had no known pertinent medical history. On 16-MAY-2008 the patient was vaccinated with dose 1 (Merck) VARIVAX (lot# was unknown). On 03-OCT-2012, sometime post vaccination child, "when child was a little over a year old", she developed shingles, which was confirmed by the doctor. The patient was seen by the doctor to seek medical attention. Child was fully recovered. Additional information has been requested.
swelling on the injection site on the left side; 4th shot on 28Mar2022; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (swelling on the injection site on the left side) and EXTRA DOSE ADMINISTERED (4th shot on 28Mar2022) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033K21-2A) for COVID-19 vaccination.     Concurrent medical conditions included Rheumatoid arthritis (started 20 years ago, Patient had it entire life, still the same).   On 28-Mar-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Mar-2022, the patient experienced EXTRA DOSE ADMINISTERED (4th shot on 28Mar2022). On 30-Mar-2022, the patient experienced VACCINATION SITE SWELLING (swelling on the injection site on the left side). At the time of the report, VACCINATION SITE SWELLING (swelling on the injection site on the left side) and EXTRA DOSE ADMINISTERED (4th shot on 28Mar2022) outcome was unknown.            No concomitant medication was reported.  Patient had never been diagnosed with or tested positive for COVID-19. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Patient stated they have received 3 shots of Moderna COVID-19 vaccine and had no problems with it.  Treatment medication was not provided by the reporter.
VEIN WAS TURNING PURPLE APPEARING BLACK AND DARK (BLACK GROWTH ON THE WRIST); RAISED SMALL BUMPS ON LEFT WRIST; This spontaneous report received from a patient concerned a 64 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient had no known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042B21A, expiry: UNKNOWN) dose was not reported, administered on 27-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 2021, the subject experienced raised small bumps on left wrist. On 10-MAY-2021, the subject experienced vein was turning purple appearing black and dark. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from vein was turning purple appearing black and dark, and the outcome of raised small bumps on left wrist was not reported. This report was non-serious.
Itchy; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65 year-old female patient received bnt162b2 (BNT162B2), administration date 03Mar2021 (Lot number: EN6203) at the age of 65 years as dose 2, single and administration date 10Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: PRURITUS (non-serious) with onset 2021, outcome "unknown", described as "Itchy". The event "itchy" was evaluated at the physician office visit. Therapeutic measures were taken as a result of pruritus. The lot number for bnt162b2 was not provided and will be requested during follow up. Additional information: Patient states that she got the vaccine last February and got the second dose by 03Mar2021. She then got the booster dose in October. Patient says that she started being itchy from the moment she got the vaccine. States that with the second dose she was itchy, itchy, itchy. States that the booster dose really set it off and she got a rash. Patient states that she has been to her doctor, dermatologist, allergist, and rheumatologist. States they have nothing besides the vaccine that is different. Patient asks is there any hope on the horizon,Will it go away, Patient states that she looked it up and saw that it is an occurrence, chronic urticaria. States that a man at her gym and a lady who just left her apartment have the same problem. Patient states that the itchiness was ongoing and she went to a dermatologist in September. Patient states at that time there was nothing there, nothing to see, just itchy. States that now she has the little tiny red dots on her back, stomach, and top of her legs. Patient states that the man at her gym had the same thing. Patient says that she google searched it recently. Patient states that she was having side effects from the Prednisone.           The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up. Sender's Comments: Linked Report(s) : US-PFIZER INC-202200474085 same product and event, different patient;US-PFIZER INC-202200474055 same product and event, different patient.
Jynneos administered intramuscularly; Case reference number US-BN-2022-001856 is a spontaneous case report initially received from a nurse via Bavarian Nordic on 09-Aug-2022 and concerns a patient of unknown demographics (seventh out of nine).  The patient's medical history and concomitant medication details were not reported.  On an unspecified date, the patient was vaccinated with a dose of Jynneos (Smallpox and Monkeypox Vaccine, Live, Nonreplicating, batch number: not provided) intramuscularly (IM), at an unknown dose or site of administration, for unknown indication (explicitly coded as 'Inappropriate route of vaccination').  At the time of this report, it was unknown whether the patient experienced any adverse event due to Jynneos.  Additional information received from Bavarian Nordic on 11-Aug-2022 included the country of occurrence.  Additional information received from Bavarian Nordic on 12-Aug-2022 included the local BN case ID.  This case is linked to cases no. US-BN-2022-001839, US-BN-2022-001851, US-BN-2022-001852, US-BN-2022-001853, US-BN-2022-001854, US-BN-2022-001855, US-BN-2022-001857 and US-BN-2022-001858, concerning the same reporter.; Reporter's Comments: The patient of unknown demographics was vaccinated with a dose of Jynneos, intramuscularly (IM), at an unknown dose or site of administration, for unknown indication which is considered as inappropriate route of vaccination. Incorrect route of product administration is considered listed per company convention. At this point, it was unknown whether the patient experienced any adverse event due to Jynneos. The patient's medical history and concomitant medication details were not reported. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: The patient of unknown demographics was vaccinated with a dose of Jynneos, intramuscularly (IM), at an unknown dose or site of administration, for unknown indication which is considered as inappropriate route of vaccination. Incorrect route of product administration is considered listed per company convention. At this point, it was unknown whether the patient experienced any adverse event due to Jynneos. The patient's medical history and concomitant medication details were not reported. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Narrative: COVID infection following COVID vaccine series 02/18, Pfizer, dose #1 01/27, Pfizer, dose #2 11/12 COVID swab, result: detected 11/19 COVID swab, result: detected 11/19 pt cc: exposure: unknown
Approximately 15 hours after receiving vaccines she had an episode at home where she began shaking and having jerking movements. Lasted approximately 2 minutes - was taken by ambulance to emergency room. Felt to be a seizure. Was afebrile. Has since had evaluation by neurologist who felt it was a seizure.
A sore swollen lymph node in the left arm pit on the 5th day.  Redness, swelling, itching at the injection site on day 7 worsening slightly on day 8
After my first two shots, my period was approx. 30 days late; This is a spontaneous report received from a contactable reporter (Consumer or other non-HCP). The reporter is the patient. A 38-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 25Mar2021 15:00 (Lot number: EN6204) at the age of 38 years as dose 2, single and administered in arm right, administration date 04Mar2021 09:00 (Lot number: EN6202) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MENSTRUATION DELAYED (disability) with onset Mar2021, outcome "recovered" (Mar2021), described as "After my first two shots, my period was approx. 30 days late". The event "after my first two shots, my period was approx. 30 days late" was evaluated at the physician office visit. Additional information: The patient stated, "I believe after the second occurrence the vaccines are to blame for my missed periods and continued lack of menstruation." The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient did not diagnose with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.  Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200028757 same reporter/patient, different vaccine dose/event
nasuea, emesis, throat irritation, hot/cold flashes.  The individual was transported to the emergency department for further observation and if necessary treatment.